- Home
- NEGG vs TVGN Comparison
NEGG vs TVGN Comparison
Compare NEGG & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEGG | TVGN |
|---|---|---|
| Founded | 2001 | 2020 |
| Country | United States | United States |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.3M | 21.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEGG | TVGN |
|---|---|---|
| Price | $14.56 | $7.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 44.4K | 4.0K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $0.14 |
| 52 Week High | $96.29 | $12.03 |
Technical Indicators
Market Signals| Indicator | NEGG | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 59.86 |
| Support Level | $12.52 | $6.41 |
| Resistance Level | $16.15 | $7.42 |
| Average True Range (ATR) | 1.10 | 0.32 |
| MACD | -0.41 | 0.04 |
| Stochastic Oscillator | 2.28 | 91.93 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.